Two months ago, analysts regarded a 20% reduction in cardiovascular events among obesity patients as the best-case scenario for Novo Nordisk A/S’s Wegovy (semaglutide injection 2.4mg). Today the vast SELECT trial hit that bullseye, driving Novo’s shares up by 18% to DKK1,285.60 ($188.67) as investors anticipate wider reimbursement and a further leap in demand.
SELECT: Novo Nordisk Comes Roaring Back
After being whipped repeatedly by Lilly’s Mounjaro, Novo’s Wegovy smashes its obesity cardiovascular outcomes trial.
